Top Page
Inoviq Ltd
(Sydney:IIQ)
Inoviq Ltd (IIQ) vs. iShares MSCI Australia ETF (EWA)
Inoviq Ltd Business Overview & Revenue Model
Inoviq Ltd Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 535.12K | 398.19K | 276.75K | 468.10K | 535.10K |
| Gross Profit | -989.82K | -1.04M | 220.30K | 404.05K | -149.80K |
| EBITDA | -6.63M | -9.02M | -5.67M | -6.05M | 0.00 |
| Net Income | -6.55M | -8.97M | -6.51M | -12.37M | -3.25M |
Balance Sheet | |||||
| Total Assets | 21.71M | 21.51M | 30.78M | 33.52M | 7.37M |
| Cash, Cash Equivalents and Short-Term Investments | 9.23M | 7.81M | 15.39M | 5.00M | 7.33M |
| Total Debt | 403.74K | 730.71K | 998.69K | 1.26M | 0.00 |
| Total Liabilities | 1.72M | 1.89M | 2.49M | 4.46M | 899.12K |
| Stockholders Equity | 19.99M | 19.62M | 28.29M | 29.06M | 6.48M |
Cash Flow | |||||
| Free Cash Flow | -4.50M | -7.32M | -6.47M | -6.05M | -2.54M |
| Operating Cash Flow | -4.32M | -7.02M | -6.06M | -5.26M | -2.54M |
| Investing Cash Flow | -174.34K | -292.27K | -411.90K | 2.64M | 0.00 |
| Financing Cash Flow | 5.91M | -267.98K | 16.87M | 286.48K | 2.31M |
Inoviq Ltd Technical Analysis
Inoviq Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | HK$15.37B | 5.69 | -7.44% | 4.08% | 11.55% | -28.15% | |
46 Neutral | AU$24.15M | ― | -104.23% | ― | ― | -17.26% | |
46 Neutral | AU$24.15M | ― | -104.23% | ― | ― | -17.26% | |
45 Neutral | AU$82.91M | ― | -47.52% | ― | 44.61% | 16.40% | |
44 Neutral | AU$18.29M | ― | -71.10% | ― | ― | 76.17% | |
44 Neutral | AU$18.29M | ― | -71.10% | ― | ― | 76.17% | |
43 Neutral | AU$41.30M | ― | -39.07% | ― | 26.07% | 0.85% | |
43 Neutral | AU$20.96M | ― | -51.49% | ― | 80.84% | 57.59% | |
43 Neutral | AU$20.96M | ― | -51.49% | ― | 80.84% | 57.59% |
Inoviq Ltd Corporate Events
INOVIQ Limited has announced that its new cancer treatment, CAR-NK-EVs, has demonstrated the ability to kill 88% of breast and lung cancer cells in laboratory tests. This advancement highlights the potential of INOVIQ’s exosome platform to offer a more efficient, safer, and potentially more effective alternative to traditional CAR-T therapies. The announcement underscores the company’s commitment to advancing cancer treatment options and may enhance its positioning within the biotechnology sector.
INOVIQ Ltd has announced a significant breakthrough in its exosome therapeutic program, with lab tests showing that its new cancer treatment kills 88% of triple-negative breast cancer and lung cancer cells. This innovative treatment uses engineered immune cell particles, CAR-NK-EVs, which target and kill cancer cells more precisely. The treatment could potentially be faster, safer, and more effective than traditional therapies, offering an ‘off-the-shelf’ solution that could benefit many patients. The next step involves testing in animal models before progressing to human clinical trials, marking a promising advancement in cancer treatment options.
Inoviq Ltd has announced that the suspension of its securities trading will be lifted following the release of further disclosure related to a recent price query. The Australian Securities Exchange (ASX) is continuing its enquiries into Inoviq’s compliance with listing rules, which may impact the company’s market operations and investor confidence.
INOVIQ Limited has announced significant results from its EXO-OC™ ovarian cancer test, presented at the American Society of Clinical Oncology Annual Meeting. The test achieved 77% sensitivity and 99.6% specificity in detecting ovarian cancer across all stages, with no missed early-stage diagnoses. This breakthrough positions INOVIQ as a leader in exosome technology, addressing the critical unmet need for early detection of ovarian cancer. The company plans to further develop and commercialize the test, seeking regulatory approval and aiming to launch it as a Laboratory Developed Test in the US, potentially saving lives by enabling earlier diagnosis and intervention.
Inoviq Ltd’s securities have been suspended from quotation on the ASX following a trading halt initiated on May 26, 2025. The suspension is due to the need for further disclosure regarding issues highlighted in the company’s price query response, and will remain until ASX confirms compliance with its Listing Rules.
INOVIQ Limited responded to an ASX price query by clarifying that the recent abstract published by the American Society of Clinical Oncology (ASCO) does not contain new, price-sensitive information beyond what was previously disclosed. However, the company highlighted the upcoming ASCO Annual Meeting presentation as potentially price-sensitive, emphasizing its confidentiality due to an ongoing patent application process. The company is adhering to ASCO’s strict embargo policies to avoid reputational and commercial risks, and it is ensuring compliance with listing rules while protecting its intellectual property.
INOVIQ Ltd has requested a trading halt on its securities pending an announcement related to an ASX Price Query response. The halt will remain in effect until the company releases the announcement or until normal trading resumes on 28 May 2025. This move is part of the company’s compliance with ASX listing rules and aims to ensure transparency and proper dissemination of information to stakeholders.
Inoviq Ltd has announced the cessation of 166,667 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could influence investor perception regarding the company’s ability to meet certain conditions tied to its securities.
INOVIQ Limited has made significant advancements in its exosome programs, including expanding its customer base for the EXO-NET technology across Europe, the US, and Asia, and developing AI-enhanced algorithms for early ovarian cancer detection. The company has also engaged the Peter MacCallum Cancer Centre to validate its CAR-exosome therapy for triple-negative breast cancer and published diagnostic performance results for its neuCA15-3 test. Additionally, INOVIQ has established a Medical and Scientific Advisory Board and appointed Dr. Emma Ball as Chief Commercial Officer. These developments are expected to enhance INOVIQ’s industry positioning and offer new therapeutic options for cancer patients.
Inoviq Ltd has announced the issuance of 150,000 unquoted equity securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize employees and align their interests with the company’s growth objectives, potentially impacting its operational dynamics and market positioning.